Antigen for avian infectious bronchitis virus antibody detection kit and indirect ELISA detection kit and application thereof
By using the nuclear protein recombinant N-protein antigen and indirect ELISA detection method of chicken infectious bronchitis virus, the problems of high antigen cost and insufficient sensitivity in the prior art are solved, and efficient and low-cost detection effect is achieved, suitable for chicken flock immunity Condition monitoring.
Patent Information
- Application Number
- CN202411439106.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
The existing methods for detecting infectious bronchitis viruses in chickens have high antigen costs, insufficient sensitivity and cross-reaction problems, making it difficult to effectively control the spread of the disease.
The purified chicken infectious bronchitis virus nuclear protein recombinant N protein was used as the antigen, and efficient and low-cost antigen was obtained through recombinant plasmid transformation and induction of expression. Combined with indirect ELISA detection methods, the specificity and sensitivity of the detection were ensured.
It has achieved efficient and low-cost antibody detection of chicken infectious bronchitis virus, with good specificity and repeatability, higher sensitivity than traditional methods, and is suitable for large-scale chicken flock immune status detection.
Smart Images

Figure CN119019516A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and in particular relates to an indirect ELISA detection kit for chicken infectious bronchitis virus antibodies and an application thereof. Background Art
[0002] Infectious bronchitis (IB) is an acute, highly contagious disease of chickens caused by infectious bronchitis virus (IBV). It is a poultry disease that seriously endangers the healthy breeding of poultry in my country and is distributed globally. Chickens of all ages are susceptible to the disease, which mainly causes the decrease in egg production and egg quality of laying hens, the decrease in weight gain and feed conversion rate of broilers, and the death of chicks due to respiratory or kidney infections. In recent years, GI-7 (TW), GI-13 (7 / 93B or 4 / 91), GI-19 (QX) and GVI-1 (TC07-2) genotypes have become the main IBV strains prevalent in my country. The prevention and control of IB in China mainly relies on vaccination with inactivated and attenuated vaccines, but due to the high variability of IBV and the lack of cross-immunity protection between different serotypes, the disease has not been effectively controlled so far.
[0003] Infectious bronchitis virus (IBV) belongs to the Coronaviridae family and the genus Gammacoronavirus. The total length of IBV is about 27.6kb, encoding four structural proteins: spike protein (S), small envelope protein (E), membrane protein (M) and nucleocapsid protein (N).
[0004] At present, a variety of IBV diagnostic methods have been established, such as chicken embryo neutralization test, agar diffusion test (AGPT), hemagglutination inhibition test (HI) and enzyme-linked immunosorbent assay (ELISA). Among these methods, ELISA has the advantages of high sensitivity, simplicity, rapidity and high specificity compared with other methods. It is conducive to detecting the immune status of large-scale chicken flocks and is the preferred method for IBV detection. Summary of the invention
[0005] Purpose of the invention: In view of the current situation that imported test kits are expensive, the present invention needs to provide an antigen for a test kit for detecting antibodies to avian infectious bronchitis virus. The antigen should have the characteristics of strong conservatism, good immunogenicity, low production price, and high expression efficiency, laying a good foundation for the preparation of the test kit. The present invention also needs to provide a test kit and a detection method for detecting antibodies to avian infectious bronchitis virus. The specific test kit and detection method provided by the present invention need to have good specificity, repeatability, that is, sensitivity.
[0006] Technical solution: In order to achieve the above-mentioned purpose, the present invention provides an antigen for an avian infectious bronchitis virus antibody detection kit, wherein the antigen is a purified recombinant N protein of the avian infectious bronchitis virus nucleoprotein.
[0007] The strain of the infectious bronchitis virus is the H120 strain, and its GenBank accession number is EU822341.1.
[0008] The steps for preparing the recombinant N protein of the infectious bronchitis virus nucleoprotein are as follows:
[0009] (1) Design amplification primers based on the IBVN gene sequence in GenBank, amplify the nucleoprotein N gene from the infectious bronchitis virus H120 strain, and recover the target gene product;
[0010] (2) Integrating the nuclear protein N gene into a plasmid vector to obtain a recombinant plasmid;
[0011] (3) transforming the recombinant plasmid to obtain a recombinant bacterial solution;
[0012] (4) Inducing the recombinant bacterial solution to express the recombinant N protein, the bacteria were lysed, and the protein was purified from the supernatant of the bacterial lysis.
[0013] Wherein, the primer sequences in step (1) are shown as SEQ ID NO.3 and SEQ ID NO.4.
[0014] Preferably, in step (1), the PCR reaction system of the nuclear protein N gene is 33 μL of water, 10 μL of 5×SF Buffer, 1 μL of 10 mM dNTP, 2 μL of 10 μmol upstream primer, 2 μL of 10 μmol downstream primer, 1 μL of cDNA template, and 1 μL of commercial Phanta Super-Fidelity DNA polymerase. The PCR amplification reaction cycle parameters are: denaturation at 94°C for 5 min; denaturation at 94°C for 30 s, annealing at 57°C for 30 s, extension at 72°C for 30 s, 30 cycles; and finally extension at 72°C for 10 min.
[0015] Preferably, in step (2), the linearized PET-28a(+) vector and the amplified nuclear protein N gene are homologously recombined to obtain a recombinant plasmid; wherein the homologous recombination reaction system is 2 μL of the linearized cloning vector, 3 μL of the amplified nuclear protein N gene, 4 μL of 5×CEⅡBuffer, 2 μL of Exnase TMⅡ enzyme, and 9 μL of ultrapure water. The reactants are placed in a PCR instrument at 37°C for 30 minutes for connection to obtain a recombinant plasmid.
[0016] Preferably, in step (3), the recombinant plasmid is transformed into BL21 Escherichia coli to obtain a recombinant bacterial solution;
[0017] Preferably, in step (4), the recombinant bacterial solution is induced to express the recombinant N protein under the induction of isopropyl β-D-1-thiogalactopyranoside at a final concentration of 1 mmol / mL, and then the bacteria are gently lysed by ultrasound, and the supernatant of the bacterial lysis is purified by using a nickel metal chelate affinity filler. The washing liquid is used for washing 15 to 25 times, and the elution liquid is used for elution 15 to 25 times, each time 1 ml. The washing liquid is a non-denaturing washing liquid, the imidazole concentration is 20 mM, and the elution liquid is a non-denaturing elution liquid, and its imidazole concentration is 50 to 500 mM.
[0018] The present invention also provides an indirect ELISA detection kit for chicken infectious bronchitis virus antibodies, characterized in that it comprises an ELISA plate coated with the recombinant N protein of the infectious bronchitis virus nucleoprotein. The preparation method of the ELISA plate coated with the recombinant N protein of the infectious bronchitis virus nucleoprotein comprises the following steps:
[0019] (1) Antigen coating: dilute the recombinant N protein to a certain concentration and add it to the wells of the ELISA plate for antigen coating. Incubate the plate at 3-5°C overnight. The next day, remove the ELISA plate, wash it, and pat it dry.
[0020] (2) Blocking: Add blocking solution to each well for blocking, then discard the blocking solution, wash and pat dry;
[0021] The indirect ELISA detection kit further comprises: coating solution, positive serum, negative serum, blocking solution, washing solution, sample diluent, HRP-labeled goat anti-chicken IgG antibody, color developing solution and stop solution.
[0022] Further, the blocking solution is a phosphate buffered saline (PBST), which contains 1% to 10% skim milk powder or 1% to 5% fetal bovine serum (FBS) or 1% to 5% bovine serum albumin (BSA); exemplary are PBST containing 5% skim milk powder, PBST containing 5% FBS, PBST containing 2% BSA, PBST containing 1% BSA, but not limited thereto. Preferably, it is PBST containing 5% skim milk powder. The sample diluent is a phosphate buffered saline (PBST), which contains 0.25% to 2% bovine serum albumin (BSA) or 0.25% to 2% skim milk powder; exemplary are PBST containing 1% BSA, PBST containing 1% skim milk powder, but not limited thereto. Preferably, it is PBST containing 1% skim milk powder. The washing solution is preferably PBST containing 0.05% Tween-20, and its pH is 7.4. The stop solution is preferably a 2M sulfuric acid solution. The positive serum is anti-IBV chicken serum, and the negative serum is SPF chicken serum (Specific Pathogen Free). The coating solution is a 0.05M sodium carbonate solution with a pH of 9.6; and the color developing solution is a TMB solution.
[0023] The application of the indirect ELISA detection kit for chicken infectious bronchitis virus antibodies of the present invention in detecting infectious bronchitis virus-specific antibodies, wherein the application method comprises the following process:
[0024] (1) Incubation of the serum to be tested: dilute the serum to be tested and add it to the wells of the ELISA plate coated with the recombinant N protein, and set up negative and positive controls. After incubation, wash and pat dry;
[0025] (2) Enzyme-labeled antibody incubation: adding diluted HRP-labeled goat anti-chicken IgG antibody to the washed wells of the ELISA plate, discarding the solution after incubation, and then washing and patting dry;
[0026] (3) Color development: Add TMB single-component color development solution to each well and develop in the dark;
[0027] (4) Stop: Add stop solution to each well to stop the reaction and measure the OD of the sample to be tested. 450nm value;
[0028] Furthermore, the sample to be tested is diluted with the above-mentioned sample diluent at a ratio of 1:200 to 1:1600 and incubated before being added to the ELISA plate, and the above-mentioned positive serum and negative serum are used to set up positive serum controls and negative serum controls; wherein, the incubation temperature is 37°C, the incubation time is 0.5 to 2h, the dilution ratio of the serum to be tested is preferably 1:400, and the incubation time is preferably 1h. HRP-labeled sheep anti-chicken IgG antibody is diluted with a ratio of 1:5000 to 1:40000 and incubated before being added to the ELISA plate, wherein, the incubation temperature is 37°C, and the incubation time is 0.5 to 2h; the enzyme-labeled antibody dilution ratio is preferably 1:20000, and the incubation time is preferably 1h. The above-mentioned color developing solution is added to the ELISA plate, and the above-mentioned stop solution is added after color development for 5 to 20 minutes, preferably 10 minutes, and finally the OD is measured. 450nm .
[0029] The standard for determining whether the sample to be tested contains infectious bronchitis virus antibodies in the present invention is: S / P ≥ 0.230 is positive, S / P < 0.230 is negative; S / P = (OD 450nm - Average OD of negative control 450nm ) / (average OD of positive control 450nm - Average OD of negative control 450nm ).
[0030] Compared with the prior art, the present invention has the following advantages:
[0031] 1. The antigen used in the present invention is the purified recombinant N protein of the nucleoprotein of infectious bronchitis virus of chickens. Compared with other structural proteins, the N protein is highly conservative. By comparing the N gene sequences of IBV-H120 strain with other strains of IBV-QX, IBV-M41, IBV-793 / B, and IBV-4 / 91 through NCBI, the homology is 87.5-99.7%. At the same time, the N protein as a functional protein is an important immunogen that induces the body's immune response, and as a detection antigen, it has great advantages in detecting antibody levels.
[0032] 2. The present invention utilizes recombinant bacteria capable of stably expressing the recombinant N protein of avian infectious bronchitis virus to induce the expression of the recombinant N protein under specific conditions. The recombinant protein has high expression efficiency, good protein purification effect, small antigen coating amount and sensitive reaction, and low preparation cost, which lays a good foundation for the preparation of low-cost test kits and effectively solves the problem of high cost of imported test kits.
[0033] 3. The recombinant N protein of infectious bronchitis virus of chickens prepared by the present invention has good specificity, has no cross reaction with standard positive sera of other common avian viruses (FAdV-4, FAdV-8a, FAdV-8b, FAdV-11, IBDV, EDSV, AIV, NDV, ALV), only reacts with positive sera of infectious bronchitis virus of chickens (IBV), and has good reaction with positive sera of four different serotypes of IBV (IBV-QX, IBV-TW, IBV-GVI, IBV-H120), and has a certain broad spectrum.
[0034] 4. The kit and detection method constructed by the present invention have good repeatability in inter-batch and intra-batch repeatability tests, and the coefficient of variation is less than 10%.
[0035] 5. The sensitivity of the kit and detection method constructed by the present invention for detecting IBV positive serum is up to 8 times that of IFA, indicating that the method has good sensitivity.
[0036] 6. The kit and detection method constructed by the present invention were tested for conformity with the imported IDEXX kit, and the test results showed a conformity rate of 91.3%, indicating that the kit has a certain reliability and can be used for the detection of IBV antibodies in clinical samples. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The electrophoresis diagram of the PCR-amplified N gene fragment and the linearized vector pET-28a(+) in Example 1 of the present invention, wherein lane M, DNA Marker; lane 1, amplified N gene fragment; lane 2, linearized pET-28a(+) vector;
[0038] Figure 2 The induced expression and purification results of the recombinant N protein in Example 1 of the present invention, wherein lane M, protein marker; lane 1, pET-28a (+) empty load precipitate; lane 2, pET-28a (+) empty load supernatant; lane 3, recombinant N protein precipitate; lane 4, recombinant N protein supernatant;
[0039] Figure 3 The immunoreactivity of the recombinant N protein identified by Western blot in Example 1 of the present invention, wherein lane M, protein marker; lane 1, pET-28a (+) empty load; lane 2, recombinant N protein; (A) Western blot result of the recombinant N protein as an antigen reacting with His monoclonal antibody (1:2000 dilution); (B) Western blot result of the recombinant N protein as an antigen reacting with IBV H120 positive chicken serum (1:1000 dilution); (C) Western blot result of the recombinant N protein as an antigen reacting with IBV QX positive chicken serum;
[0040] Figure 4 It is a detection diagram of the product during the purification process of the recombinant N protein in Example 1 of the present invention, wherein lane M is a protein marker; lane 1, pET-28a (+) empty supernatant; lane 2, recombinant protein induced supernatant; lane 3, recombinant protein binding supernatant; lane 4, 50mM imidazole eluent; lane 5, 100mM imidazole eluent; lane 6, 250mM imidazole eluent; lane 7, 500mM imidazole eluent;
[0041] Figure 5 The figure is a test result diagram of different blocking solutions and blocking times in Example 2;
[0042] Figure 6 Graph showing the test results of different sample dilutions and primary antibody incubation times in Example 2;
[0043] Figure 7 The figure is a test result diagram of different secondary antibody dilution multiples and secondary antibody incubation times in Example 2;
[0044] Figure 8 It is the detection result diagram of different color development times in Example 2;
[0045] Fig. 9 It is the specificity test result figure in Example 3;
[0046] Fig.10 This is the IFA diagram of detecting 4 chicken sera in Example 3. DETAILED DESCRIPTION
[0047] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0048] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources. Experimental methods without specific conditions specified in the examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0049] Positive sera of avian adenovirus (FAdv-4, FAdv-8a, FAdv-8b, FAdv-11), infectious bursal disease virus (IBDV), egg drop syndrome virus (EDS-YH99), avian influenza virus (AIV), Newcastle disease virus (NDV), J subgroup avian leukosis virus (ALV-J), infectious bronchitis virus (IBV-QX, IBV-TW, IBV-GVI, IBV-H120) and 46 chicken sera immune to IBV were provided by Sinopharm Yangzhou Weike Bioengineering Co., Ltd., all of which are sera of common avian viruses and are preserved by Yangzhou University. 50 SPF chicken sera, 25 clinically uninfected IBV chicken sera and 12 anti-IBV positive chicken sera, the serum preparation method is a common known technology, preserved and provided by Yangzhou University.
[0050] H120 vaccine was purchased from China Veterinary Drug Inspection Institute, His-Tag monoclonal antibody was purchased from Pasteur Biotechnology, horseradish peroxidase (HRP)-labeled goat anti-chicken IgG and fluorescein isothiocyanate (FITC)-labeled rabbit anti-chicken IgG were purchased from Jackson Immuno Research; TMB single-component colorimetric solution was purchased from Solarbio; 96-well ELISA plate was purchased from Corning; imported IBV IDEXX ELISA detection kit was purchased from IDEXX Company, catalog number 99-09262.
[0051] Example 1
[0052] This embodiment provides a method for preparing high-purity IBV recombinant N protein, which specifically includes:
[0053] 1.1 Amplification of IBV N gene fragment and linearization of pET-28a(+) vector
[0054] (1) Using the total RNA extracted from IBV H120 as a template, cDNA was synthesized by RT-PCR. The specific operation was as follows: Add reaction system A to an enzyme-free tube and centrifuge at low speed, heat reaction system A at 65°C for 5 min, and place it on ice for 2 min. Then, add the final solution of reaction system A to reaction system B and centrifuge at low speed. Reverse transcription was performed on a PCR instrument. The program was: 50°C for 45 min, 85°C for 5 min. Finally, the obtained cDNA was stored for future use.
[0055] Reaction system A:
[0056]
[0057] Reaction system B:
[0058]
[0059] (2) Design upstream and downstream primers for amplifying the N gene of the H120 strain (GenBank accession number EU822341.1) and the linearized pET-28a(+) vector. Specifically, the designed primer sequences are as follows:
[0060]
[0061] (3) PCR amplification was performed using the designed primers to obtain the amplified N gene and the linearized pET-28a(+) vector.
[0062] The PCR system is as follows:
[0063]
[0064] The PCR amplification reaction cycle parameters are: 94℃ pre-denaturation for 5min; 94℃ denaturation for 30s, 57℃ annealing for 30s, 72℃ extension (30s / 1kb), 30 cycles; and finally 72℃ extension for 10min. After the PCR is completed, the PCR product is electrophoresed in 1% agarose gel. The band is consistent with the expected size, and the band is cut off, and the DNA fragment is recovered according to the instructions of the agarose gel DNA recovery kit.
[0065] 1.2 Construction of recombinant plasmid
[0066] The two recovered DNA products were homologously recombined. The reaction system was as follows: the reactants were placed in a PCR instrument at 37°C for 30 minutes for connection, and the products could be transformed after the reaction was completed.
[0067]
[0068] 1.3 Recombinant plasmid transformation and recombinant bacteria preparation
[0069] The recombinant plasmid was transformed into DH5α Escherichia coli. The specific transformation steps were as follows: DH5α was thawed on ice, 10 μL of the recombinant product was added to the host bacteria, and it was placed on ice for 30 minutes; after heat shock in a 42°C water bath for 60 seconds, it was immediately placed on ice for 2 minutes, 900 μL of non-antibiotic culture medium was added, and the bacteria were shaken at 37°C for 1 hour; 100 μL of bacterial solution was spread on kanamycin-resistant LB solid culture medium, cultured overnight, and bacterial clones were picked for colony identification the next day, and positive clones were sequenced. There is no special limitation on the transformation method in the present invention, and the transformation method known in the art can be used.
[0070] 1.4 Inducible expression of recombinant protein
[0071] The positive clones were transformed into BL21 competent cells according to the above transformation method, and the bacterial solution was plated and cultured overnight. A single colony was picked and added to LB liquid culture medium containing kanamycin, and pET-28a (+) empty vector bacteria were set as negative control group. The bacterial solution was shaken at 37°C and 220 rpm until OD 600 When the pH value was ≈0.6, isopropyl β-D-1-thiogalactopyranoside was added at a final concentration of 1 mmol / L to induce protein expression. After 4 hours, the bacterial solution was placed in a 4°C ultracentrifuge at 8000 rpm for 10 minutes, the supernatant was discarded, and the precipitate was resuspended with 5 mL PBS. After centrifugation again, 1 mL PBS was added and resuspended in an ultrasonic crusher for ultrasonic crushing. The working procedure was: 40 Hz, ultrasonic 2s, and rest 6s. The recombinant protein solution was obtained by ultrasonication until it was clear.
[0072] 1.5 SDS-PAGE and Western blot verification of recombinant protein
[0073] After centrifugation of the ultrasonically disrupted samples, the supernatant and precipitate were separated to prepare protein samples. SDS-PAGE and Western blot (with His-Tag monoclonal antibody and IBV-H120 positive chicken serum as primary antibodies) showed that the recombinant N protein was expressed in a soluble form and was consistent with the expected size ( Figure 2 ), which can react specifically with IBV-positive serum ( Figure 3 ).
[0074] 1.6 Recombinant protein purification
[0075] According to the instruction manual of the His-tag protein purification kit (denaturation-resistant formulation) of Biyuntian, the supernatant of bacterial lysis was purified using nickel metal chelate affinity filler. The purification conditions were as follows: the washing solution was a non-denaturing washing solution with an imidazole concentration of 20 mM, and the washing was performed 20 times with 1 mL / time; the elution solution was a non-denaturing elution solution with an imidazole concentration of 500 mM, and the elution was performed 20 times with 1 mL / time; Figure 4 It can be seen that the IBV recombinant N protein expressed by the engineered bacteria is effectively purified by the nickel column, that is, the purified recombinant N protein antigen of infectious bronchitis virus of chickens. After sequencing, its amino acid sequence is shown in SEQ ID NO.2, and the coding gene of the recombinant N protein is shown in SEQ ID NO.1.
[0076] Example 2
[0077] Establishment and optimization of indirect ELISA method for infectious bronchitis virus in chickens
[0078] (1) Add 100 μL of an antigen solution of 1 ug / mL infectious bronchitis virus recombinant N protein to each well of a 96-well ELISA plate and coat overnight at 4°C; the coating solution is a 0.05 M sodium carbonate solution with a pH of 9.6.
[0079] (2) The next day, after removing the coating solution, wash with the washing solution three times and pat dry, add 360 μL of blocking solution to each well and block at 37°C for 2 h. The blocking solution is a PBST solution containing 5% skim milk, and the washing solution is a PBST solution containing 0.05% Tween-20.
[0080] (3) Positive and negative serum controls were set up. The positive serum was anti-IBV chicken serum, and the negative serum was SPF chicken serum. PBST solution was selected as the serum sample diluent. The standard positive and negative serum was diluted 1:400. After incubation at 37°C for 1 hour, the plate was washed three times with 0.05% Tween-20 PBST solution and patted dry.
[0081] (4) Add 100 μL of diluted HRP-labeled goat anti-chicken IgG to each well. Use PBST solution as the diluent and dilute HRP-labeled goat anti-chicken IgG at a ratio of 1:10000. Incubate at 37°C for 1 h, rinse three times with 0.05% Tween-20 in PBST solution and pat dry.
[0082] (5) Add 100 μL of TMB colorimetric reagent to each well and react at room temperature in the dark for 10 min to develop color.
[0083] (6) Add 50 μL 2M H2SO4 to each well to terminate the reaction and measure the OD using an ELISA reader. 450nm Absorbance value.
[0084] 2.1 Optimization of optimal antigen coating concentration and serum dilution
[0085] According to the above method, the recombinant N protein was diluted in a gradient ratio to a concentration of 4, 3, 2, 1, 0.5, 0.25, 0.125, 0.0625 μg / mL, and the diluted protein was added to the ELISA plate from left to right, 100 μL / well, and incubated at 4°C overnight; the next day, it was washed 3 times with PBST; the blocking solution was 360 μL / well, and blocked at 37°C for 2 hours. The standard positive and negative serum was diluted in a gradient ratio of 1:200, 1:400, 1:800, 1:1600, 100 μL / well, and added to the ELISA plate from top to bottom, and incubated at 37°C for 1 hour. The positive serum OD was selected 450nm Values are approximately 1.0 and negative serum OD 450nm The dilution of the coated antigen corresponding to the result with a lower value is the optimal concentration of the antigen coating, and the corresponding dilution of the negative and positive serum is the optimal dilution multiple of the serum. The results are shown in Table 1. The optimal antigen coating concentration is 0.25μg / mL, and the optimal serum dilution multiple is 1:400.
[0086] Table 1 Optimal antigen coating concentration and serum dilution multiples determined by the chessboard method
[0087]
[0088] 2.2 Optimization of the best blocking solution and blocking time
[0089] According to the above method, the optimal antigen coating concentration and the optimal serum dilution multiple were used, and PBST containing 5% skim milk, 5% fetal bovine serum (FBS), 2% bovine serum albumin (BSA), and 1% BSA was used as the blocking solution. The cells were placed in a constant temperature incubator at 37°C for blocking for 0.5h, 1h, 1.5h, 2h, and 2.5h respectively. The combination with the largest P / N was selected to determine the optimal blocking solution and blocking time. The results are shown in Figure 5 As shown, it was found that the P / N value was the largest when the cells were blocked with PBST containing 5% skim milk for 1 h.
[0090] 2.3 Optimization of optimal sample dilution and incubation time
[0091] According to the above optimization method, PBST, PBST containing 1% skim milk, and 1% BSA were used as sample diluents, and incubated at 37°C for 0.5h, 1h, 1.5h, and 2h. The combination with the largest P / N value was selected to determine the optimal sample diluent and incubation time. The results are shown in Figure 6 As shown, it was found that the P / N value was the largest when PBST containing 1% skim milk was used as the sample diluent for incubation for 1 hour.
[0092] 2.4 Optimization of the optimal secondary antibody dilution and incubation time
[0093] Based on the above results, the dilution and action time of the secondary antibody were optimized according to the above optimization method. HRP-labeled goat anti-chicken IgG diluted 5000, 10000, 20000, 30000, and 40000 times with PBST was added and placed in a 37°C constant temperature incubator for incubation for 0.5h, 1h, 1.5h, and 2h respectively. The optimal secondary antibody dilution multiple and incubation time were determined according to the maximum P / N value combination. The results are shown in Figure 2. Figure 7 The results showed that the P / N value was the largest when the sheep anti-chicken IgG was diluted 20,000 times and incubated for 1 hour.
[0094] 2.5 Optimization of the best color development time
[0095] Based on the above results, the color development time was optimized according to the above optimized method. TMB single component substrate was incubated at room temperature for 5min, 10min, 15min, and 20min respectively. The optimal color development time was determined according to the maximum P / N value. The results are shown in Figure 8 As shown, it was found that the P / N value was the largest when the TMB substrate reaction time was 10 min.
[0096] Therefore, the optimal kit composition is:
[0097] (1) Coating solution (1× carbonate buffer): 0.159 g Na2CO3, 0.293 g NaHCO3, dissolved in distilled water and diluted to 100 mL, pH 9.6, stored at 4°C;
[0098] (2) 1× PBS solution: 4 g NaCl, 0.1 g KCl, 1.815 g Na2HPO412H2O, 0.12 g KH2PO4, dissolved in distilled water and fixed to 500 mL, pH 7.4; washing solution (PBST): add 0.5 mL Tween-20 to every 1 L PBS solution and mix thoroughly;
[0099] (3) Blocking solution: Dissolve 2.5 g skim milk in 50 mL PBST and mix thoroughly;
[0100] (4) Sample diluent: Dissolve 0.5 g skim milk in 50 mL PBST and mix thoroughly;
[0101] (5) Enzyme labeling reagent: horseradish peroxidase-labeled goat anti-chicken antibody, 5 mL;
[0102] (6) TMB single-component substrate colorimetric solution: 200 mL;
[0103] (7) 2M H2SO4 stop solution: 100 mL;
[0104] (8) Standard positive control: 5 mL;
[0105] (9) Standard negative control: 5 mL.
[0106] The optimal indirect ELISA test method is as follows:
[0107] (1) Dilute the recombinant N protein to 0.25 μg / mL with coating solution, then add 100 μL to each well of a 96-well ELISA plate for coating. Place the plate at 4°C overnight. The coating solution is a 0.05 M sodium carbonate solution with a pH of 9.6. The plate is removed the next day, rinsed three times with PBST containing 0.05% Tween-20, and patted dry.
[0108] (2) Add 360 μL of PBST solution containing 5% skim milk to each well of a 96-well ELISA plate for blocking (freshly prepared and used), incubate at 37°C for 1 h, rinse once with PBST and pat dry (can be stored at 4°C for a short period of time);
[0109] (3) Dilute the serum at 1:400 using PBST containing 1% skim milk as the sample diluent, then add 100 μL of the serum to be tested to each well, and set up positive and negative controls with the same dilution. After incubation at 37°C for 1 h, rinse the ELISA plate three times with PBST containing 0.05% Tween-20 and pat dry.
[0110] (4) Dilute HRP-labeled goat anti-chicken IgG with PBST solution containing 1% skim milk at a ratio of 1:20,000, then add 100 μL of enzyme-labeled secondary antibody to each well, incubate at 37°C for 1 h, rinse the ELISA plate three times with PBST containing 0.05% Tween-20 and pat dry;
[0111] (5) Finally, add 100 μL of TMB colorimetric solution to each well of the 96-well ELISA plate and react at room temperature in the dark for 10 min. Then add 50 μL of 2M H2SO4 stop solution to each well to terminate the reaction. Quickly measure the OD of each well using an ELISA reader. 450nm values, record data, and analyze results.
[0112] 2.6 Determination of critical value
[0113] Take 50 SPF chicken sera and 25 clinically uninfected IBV chicken sera as the test sera, and use the above optimized ELISA reaction system to detect the serum antibody OD 450nm The S / P value is calculated, S / P = (OD 450nm - Average OD of negative control 450nm ) / (average OD of positive control 450nm - Average OD of negative control 450nm ), the average value X and standard deviation S of the S / P value of the serum samples were calculated as the critical standard for the negative and positive determination of the ELISA method. After calculation, the average value X of the S / P value of the above 75 negative sera was 0.107, the standard deviation S was 0.041, and the ELISA positive and negative critical value was X+3S=0.230, so S / P≥0.230 was judged as positive, and S / P<0.230 was judged as negative.
[0114] Table 2 Critical value determination
[0115]
[0116] Example 3
[0117] Specificity experiments
[0118] According to the optimal kit and detection method established in Example 2, positive sera of avian adenovirus (FAdV-4, FAdV-8a, FAdV-8b, FAdV-11), infectious bursal disease virus (IBDV), egg drop syndrome virus (EDSV-YH99), avian influenza virus (AIV), Newcastle disease virus (NDV), subgroup J avian leukosis virus (ALV-J) and infectious bronchitis virus (IBV-QX, IBV-TW, IBV-GVI, IBV-H120) and SPF chicken sera were detected. The test results are as follows. Fig. 9 As shown, except for the positive reaction of infectious bronchitis virus, the positive serum tests of other pathogens were all negative, indicating that the kit has good specificity and good compatibility with different serotypes of IBV.
[0119] Example 4
[0120] Repeatability experiment
[0121] Take 3 ELISA plates coated at the same time and perform an intra-batch repeatability experiment. According to the optimal kit and detection method of Example 2, 5 IBV positive sera (including two IBV-H120, one IBV-QX, one IBV-TW, and one IBV-GVI) and 3 SPF negative chicken sera were tested under the same conditions. The mean value (X), standard deviation (SD) and coefficient of variation (CV) of the samples were calculated, and an intra-batch repeatability analysis was performed. The calculation formula is CV=(SD / X)×100%. The test results are shown in Table 3. The CV value of the intra-batch repeatability test is between 2.68 and 5.93%, which proves that the intra-batch repeatability of the kit is good.
[0122] Table 3 Intra-batch repeatability experiment
[0123]
[0124] Take 3 ELISA plates coated at different times (Day 1, Day 3, Day 5) and perform batch repetition test. According to the optimal kit and detection method of Example 2, 5 IBV positive sera (including two IBV-H120, one IBV-QX, one IBV-TW, one IBV-GVI) and 3 SPF negative chicken sera were tested under the same conditions for batch repetition test. The test results were statistically analyzed. The test results are shown in Table 4. The CV value of the batch repetition test is between 2.40 and 7.15%, which proves that the batch repetition of the kit is good.
[0125] Table 4 Inter-batch repeatability experiment
[0126]
[0127]
[0128] Example 5
[0129] Sensitivity test
[0130] Four anti-IBV positive chicken sera (IBV-H120, IBV-GVI, IBV-TW, IBV-QX) were serially diluted for IFA detection, and ELISA detection was performed using the optimal kit and detection method of Example 2. The test results are shown in Table 5, and the sensitivity of this kit is 8 times that of IFA, which has good sensitivity.
[0131] The specific IFA detection steps are as follows:
[0132] First, IBV H120 strain (TCID50 = 10 3 / mL) was used to infect CEK cells, and the cell culture supernatant was discarded after 60 hours. Each well was fixed with 60 μL of 3:2 acetone ethanol fixative for 5 minutes, and the cells were washed once with PBS and then blown dry; then 100 μL of diluted chicken serum was added to the fixed cell plate at each well, incubated at 37°C for 45 minutes, and washed three times with PBS; 60 μL of fluorescein isothiocyanate (FITC)-labeled rabbit anti-chicken IgG secondary antibody diluted 1:150 was added to each well, incubated at 37°C for 45 minutes, and washed three times with PBS; finally, 50 μL of PBS was added to each well, the cell plate was placed under a fluorescence microscope for observation, and the green fluorescence of each well was recorded ("+" indicates that the test result has green fluorescence, which is positive, and "-" indicates that the test result has no green fluorescence, which is negative).
[0133] Table 5 Comparison of sensitivity between ELISA and IFA
[0134]
[0135] Example 6
[0136] Compliance test
[0137] In order to test the compliance rate of the kit, 46 immune chicken sera from Yangzhou Weike Bioengineering Co., Ltd. of Sinopharm Group were tested using the present invention and the imported IDEXX kit (American IDEXX Biotechnology Company, Article No. 99-09262). The IDEXX kit manual operation steps are as follows: first, the ELISA plate and the reagents in the kit are taken out from 4°C and restored to room temperature; then the serum to be tested is diluted by 1:500 using the antibody diluent in the kit, and 100 μL per well is added to the ELISA plate, and the positive and negative controls in the kit are added at the same time. After reacting at room temperature for 30 minutes, the supernatant is discarded and washed 5 times with ultrapure water in the kit; 100 μL of the enzyme-labeled secondary antibody in the box is added to each well, specifically, oxidase (HRP)-labeled sheep anti-chicken IgG, and reacted at room temperature for 30 minutes; the secondary antibody is discarded and washed 5 times with ultrapure water; 100 μL of the TMB colorimetric solution in the box is added to each well, incubated at room temperature for 15 minutes, 100 μL of the stop solution is added to stop the reaction, and the OD is read on the ELISA instrument 650nm According to the positive and negative readings, the S / P value of each sample is calculated, S / P = (OD 650nm - Average OD of negative control 650nm ) / (average OD of positive control 650nm - Average OD of negative control 650nm), S / P ≥ 0.20 determined the sample to be positive, and S / P < 0.20 determined it to be negative.
[0138] The standard for determining whether the sample to be tested contains infectious bronchitis virus antibodies using the optimal kit and detection method in Example 2 of the present invention is: S / P ≥ 0.230 is positive, and S / P < 0.230 is negative. S / P = (OD 450nm - Average OD of negative control 450nm ) / (average OD of positive control 450nm - Average OD of negative control 450nm ).
[0139] As shown in Table 6 (all tables are S / P values) and Table 7, the test results of the test kit established by the present invention were 37 positive and 9 negative, and the test results of the imported IDEXX test kit were 39 positive and 7 negative. The conformity rate between the present invention and the IDEXX test kit was 91.30%, which is a high conformity rate. Specifically comparing the test results of the two methods, it was found that the test results of 4 serum samples were inconsistent. The IFA test of these 4 serum samples was performed, and the test results were all positive. The test results are as follows Fig.10 shown.
[0140] Table 6 Comparison of the test results of the present invention and IDEXX test kit
[0141]
[0142] Table 7 The consistency of the test results of this kit and the IDEXX imported kit
[0143]
Claims
1. An antigen for detecting antibodies to avian infectious bronchitis virus, characterized in that: The antigen is the purified recombinant N protein of the nucleoprotein of avian infectious bronchitis virus, the coding gene of the recombinant protein is shown in SEQ ID NO.1, and the amino acid sequence of the recombinant N protein is shown in SEQ ID NO.
2.
2. The antigen for detecting antibodies to avian infectious bronchitis virus according to claim 1, characterized in that: The strain of the avian infectious bronchitis virus is the H120 strain, and its GenBank accession number is EU822341.
1.
3. The antigen for detecting antibodies to avian infectious bronchitis virus according to claim 1, characterized in that: The steps for preparing the recombinant N protein are as follows: (1) Design amplification primers based on the IBVN gene sequence in GenBank, amplify the nucleoprotein N gene from the infectious bronchitis virus H120 strain, and recover the target gene product; (2) The nuclear protein N gene is integrated into the plasmid vector to obtain a recombinant plasmid; (3) transforming the recombinant plasmid to obtain a recombinant bacterial solution; (4) The recombinant bacterial solution is induced to express the recombinant protein, and then the bacteria are lysed, and the protein is purified from the supernatant of the bacterial lysis.
4. The method according to claim 3, wherein the antigen for detecting antibodies to avian infectious bronchitis virus is: The primers in step (1) are: CGCGGATCCGAATTCGCGAGCGGTAAGACAA,TGGTGGTGCTCGAGTAAGTTCATTCTCTCC.
5. An indirect ELISA test kit for chicken infectious bronchitis virus antibody, characterized in that: The invention comprises an ELISA plate coated with the recombinant N protein of the avian infectious bronchitis virus according to claims 1-4.
6. The indirect ELISA detection kit for chicken infectious bronchitis virus antibody according to claim 5, characterized in that: The indirect ELISA detection kit preferably also includes: coating solution, positive serum, negative serum, blocking solution, washing solution, sample diluent, HRP-labeled goat anti-chicken IgG antibody, color development solution and stop solution.
7. The indirect ELISA detection kit for chicken infectious bronchitis virus antibody according to claim 6, characterized in that: The method for preparing an ELISA plate coated with recombinant N protein of avian infectious bronchitis virus comprises the following steps: (1) Antigen coating: dilute the recombinant N protein to 0.2-0.3 μg / mL and add it to the wells of the ELISA plate for antigen coating. Incubate the plate at 3-5°C overnight. The next day, remove the ELISA plate, wash it, and pat it dry. (2) Blocking: Add blocking solution to each well for blocking, then discard the blocking solution, wash and pat dry.
8. Use of the indirect ELISA detection kit for chicken infectious bronchitis virus antibody according to claim 5 in detecting infectious bronchitis virus-specific antibodies.
9. The use according to claim 8, characterized in that: The application method comprises the following process: (1) Incubation of serum to be tested: dilute the serum sample to be tested and add it to the wells of the ELISA plate coated with the recombinant N protein. Set up negative and positive serum controls at the same time. After incubation, wash and pat dry. (2) Enzyme-labeled antibody incubation: Add diluted HRP-labeled goat anti-chicken IgG antibody to the washed ELISA plate, discard the solution after incubation, and then wash and pat dry; (3) Color development: Add TMB single-component color development solution to each well and develop in the dark; (4) Stop: Add stop solution to each well to stop the reaction and measure the OD of the sample to be tested. 450nm value; (5) The criteria for determining whether the sample to be tested contains infectious bronchitis virus antibodies are: S / P ≥ 0.230 for positive, S / P < 0.230 for negative; S / P = (OD 450nm - Average OD of negative control 450nm ) / (average OD of positive control 450nm - Average OD of negative control 450nm ).
